Effects of chronic corticotrophin treatment on aldosterone metabolism in the rat.
Chronic treatment with high doses of ACTH leads to marked reduction in aldosterone biosynthesis and secretion both in vivo and in vitro. In contrast, it has been reported that peripheral plasma aldosterone levels may be elevated following prolonged ACTH treatment. The present study attempts to determine the reason(s) for this apparently paradoxical finding. ACTH treatment (40 micrograms/100 g body weight) of male Sprague-Dawley rats for 7 days caused a decrease of more than 90% in aldosterone secretion into the adrenal vein in vivo and aldosterone production by intact adrenal capsules incubated in vitro. In contrast, peripheral plasma aldosterone levels appeared to be increased when measured by radioimmunoassay using two different polyclonal antibodies (antibody 1 (AB1) raised against aldosterone-3-carboxymethyloxime-bovine serum albumin (BSA) and antibody 2 (AB2) raised against aldosterone-21-hemisuccinate-BSA). However, when a highly specific monoclonal antibody (raised against aldosterone-3-carboxymethyloxime-BSA and showing low cross-reactivity to aldosterone metabolites) was used, peripheral plasma aldosterone levels appeared to be reduced in ACTH-treated rats. Following chromatographic fractionation of peripheral plasma, significantly more material with aldosterone-like immuno-reactivity, but which was less polar than authentic aldosterone in chromatographic mobility, was detected in the fractions using antibodies AB1 and AB2. The absence of this material from fractions of adrenal vein plasma leads us to infer that this material is generated in the peripheral circulation, probably as a result of hepatic metabolism. In addition, the overall metabolic clearance rate (MCR) of [3H] aldosterone was found to be significantly decreased following prolonged ACTH treatment. We conclude that the seemingly discrepant findings with regard to the effects of chronic ACTH treatment on peripheral plasma aldosterone levels and the secretion of aldosterone in vivo can be reconciled by (1) the changes in the overall MCR of aldosterone and (2) the generation of increased quantities of aldosterone metabolites such as 5 alpha-dihydroaldosterone and 3 alpha, 5 beta-tetrahydroaldosterone which show significant cross-reactivity with some aldosterone antibodies.
Biomedical Sciences Division, King's College London, U.K.
D R
DR
Abayasekara
N I
NI
Onyezili
B J
BJ
Whitehouse
S M
SM
Laird
G P
GP
Vinson
D000311:Adrenal Glands / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000450:Aldosterone / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley
D000450:Aldosterone; D000324:Adrenocorticotropic Hormone